Do analysts rate QURE or AVTE?

uniQure currently has a consensus target price of $42.83, indicating a potential upside of 58.70%. Given uniQure's stronger consensus rating and higher probable upside, equities analysts plainly believe uniQure is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score uniQure 1 Sell rating(s) 6 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.53 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer AVTE or GENB?

Generate Biomedicines has a consensus target price of $25.40, suggesting a potential upside of 89.98%. Given Generate Biomedicines' stronger consensus rating and higher possible upside, analysts clearly believe Generate Biomedicines is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Generate Biomedicines 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86

Which has better earnings & valuation, AVTE or GENB?

Generate Biomedicines has higher revenue and earnings than Aerovate Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A Generate Biomedicines $30.30M 56.57 N/A N/A N/A

Is AVTE or GENB more profitable?

Generate Biomedicines' return on equity of 0.00% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aerovate Therapeutics N/A -90.19% -77.47% Generate Biomedicines N/A N/A N/A

Do analysts prefer AVTE or BHVN?

Biohaven has a consensus price target of $22.27, suggesting a potential upside of 83.78%. Given Biohaven's stronger consensus rating and higher probable upside, analysts plainly believe Biohaven is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Biohaven 1 Sell rating(s) 5 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.71

Which has preferable valuation & earnings, AVTE or BHVN?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A Biohaven N/A N/A -$738.82M -$5.67 N/A

Is AVTE or BHVN more profitable?

Aerovate Therapeutics' return on equity of -90.19% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Aerovate Therapeutics N/A -90.19% -77.47% Biohaven N/A -866.46% -137.99%

Do analysts rate NUVB or AVTE?

Nuvation Bio currently has a consensus target price of $12.50, indicating a potential upside of 144.24%. Given Nuvation Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Nuvation Bio is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvation Bio 2 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.55 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate AVTE or ABCL?

AbCellera Biologics has a consensus price target of $7.80, suggesting a potential upside of 53.24%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, analysts clearly believe AbCellera Biologics is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 AbCellera Biologics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67

Aerovate Therapeutics (AVTE) Competitors

$16.10 +0.76 (+4.95%)

As of 06/15/2026

Compare

AVTE vs. QURE, GENB, BHVN, NUVB, and ABCL

Should you buy Aerovate Therapeutics stock or one of its competitors? MarketBeat compares Aerovate Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aerovate Therapeutics include uniQure (QURE), Generate Biomedicines (GENB), Biohaven (BHVN), Nuvation Bio (NUVB), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry.

How does Aerovate Therapeutics compare to uniQure?

uniQure (NASDAQ:QURE) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

uniQure has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

78.8% of uniQure shares are held by institutional investors. 4.7% of uniQure shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Aerovate Therapeutics has lower revenue, but higher earnings than uniQure. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	105.73	-$198.97M	-$3.48	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Aerovate Therapeutics has a net margin of 0.00% compared to uniQure's net margin of -1,154.42%. Aerovate Therapeutics' return on equity of -90.19% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,154.42%	-145.81%	-27.15%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

uniQure currently has a consensus target price of $42.83, indicating a potential upside of 58.70%. Given uniQure's stronger consensus rating and higher probable upside, equities analysts plainly believe uniQure is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, uniQure had 16 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 16 mentions for uniQure and 0 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 0.00 beat uniQure's score of -0.22 indicating that Aerovate Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
uniQure	Neutral
Aerovate Therapeutics	Neutral

Summary

uniQure beats Aerovate Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Generate Biomedicines?

Aerovate Therapeutics (NASDAQ:AVTE) and Generate Biomedicines (NASDAQ:GENB) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

In the previous week, Generate Biomedicines had 1 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 1 mentions for Generate Biomedicines and 0 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 0.00 equaled Generate Biomedicines'average media sentiment score.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
Generate Biomedicines	Neutral

Generate Biomedicines has higher revenue and earnings than Aerovate Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Generate Biomedicines	$30.30M	56.57	N/A	N/A	N/A

Generate Biomedicines has a consensus target price of $25.40, suggesting a potential upside of 89.98%. Given Generate Biomedicines' stronger consensus rating and higher possible upside, analysts clearly believe Generate Biomedicines is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Generate Biomedicines' return on equity of 0.00% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Generate Biomedicines	N/A	N/A	N/A

Summary

Generate Biomedicines beats Aerovate Therapeutics on 7 of the 7 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Biohaven?

Aerovate Therapeutics (NASDAQ:AVTE) and Biohaven (NYSE:BHVN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

88.8% of Biohaven shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by company insiders. Comparatively, 13.8% of Biohaven shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Aerovate Therapeutics' average media sentiment score of 0.00 equaled Biohaven'saverage media sentiment score.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
Biohaven	Neutral

Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Biohaven has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

Biohaven has a consensus price target of $22.27, suggesting a potential upside of 83.78%. Given Biohaven's stronger consensus rating and higher probable upside, analysts plainly believe Biohaven is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Biohaven	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.71

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A

Aerovate Therapeutics' return on equity of -90.19% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Biohaven	N/A	-866.46%	-137.99%

Summary

Biohaven beats Aerovate Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Nuvation Bio?

Nuvation Bio (NYSE:NUVB) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

61.7% of Nuvation Bio shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Aerovate Therapeutics has a net margin of 0.00% compared to Nuvation Bio's net margin of -102.06%. Nuvation Bio's return on equity of -44.10% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-102.06%	-44.10%	-23.80%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

In the previous week, Nuvation Bio had 4 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 4 mentions for Nuvation Bio and 0 mentions for Aerovate Therapeutics. Nuvation Bio's average media sentiment score of 1.24 beat Aerovate Therapeutics' score of 0.00 indicating that Nuvation Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Nuvation Bio	Positive
Aerovate Therapeutics	Neutral

Nuvation Bio has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

Aerovate Therapeutics has lower revenue, but higher earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	28.33	-$204.63M	-$0.43	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Nuvation Bio currently has a consensus target price of $12.50, indicating a potential upside of 144.24%. Given Nuvation Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Nuvation Bio is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Nuvation Bio beats Aerovate Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Aerovate Therapeutics compare to AbCellera Biologics?

Aerovate Therapeutics (NASDAQ:AVTE) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

AbCellera Biologics has a consensus price target of $7.80, suggesting a potential upside of 53.24%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, analysts clearly believe AbCellera Biologics is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

61.4% of AbCellera Biologics shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

Aerovate Therapeutics has higher earnings, but lower revenue than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
AbCellera Biologics	$75.13M	20.69	-$146.41M	-$0.48	N/A

Aerovate Therapeutics has a net margin of 0.00% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
AbCellera Biologics	-181.75%	-14.86%	-10.62%

In the previous week, AbCellera Biologics had 1 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 1 mentions for AbCellera Biologics and 0 mentions for Aerovate Therapeutics. AbCellera Biologics' average media sentiment score of 0.25 beat Aerovate Therapeutics' score of 0.00 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
AbCellera Biologics	Neutral

Summary

AbCellera Biologics beats Aerovate Therapeutics on 13 of the 16 factors compared between the two stocks.

Get Aerovate Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVTE vs. The Competition

Export

Metric	Aerovate Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$466.66M	$763.44M	$6.49B	$12.35B
Dividend Yield	N/A	4.84%	2.67%	5.66%
P/E Ratio	-5.38	1.43	23.87	24.26
Price / Sales	N/A	127.26	524.24	106.62
Price / Cash	N/A	20.06	44.13	56.68
Price / Book	4.07	7.92	10.50	6.69
Net Income	-$75.52M	-$4.88M	$3.56B	$337.12M
7 Day Performance	5.78%	2.08%	0.88%	2.17%
1 Month Performance	-31.06%	1.63%	1.53%	3.64%
1 Year Performance	130.33%	44.88%	26.46%	29.77%

Aerovate Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVTE Aerovate Therapeutics	N/A	$16.10 +5.0%	N/A	+138.2%	$466.66M	N/A	N/A	20	Gap Up High Trading Volume
QURE uniQure	2.0437 of 5 stars	$26.46 -2.0%	$42.83 +61.9%	+78.6%	$1.70B	$16.10M	N/A	500
GENB Generate Biomedicines	N/A	$13.19 +3.2%	$25.40 +92.6%	N/A	$1.69B	$30.30M	N/A	312
BHVN Biohaven	2.3756 of 5 stars	$11.11 -0.1%	$22.27 +100.4%	-20.3%	$1.67B	N/A	N/A	239
NUVB Nuvation Bio	3.5175 of 5 stars	$4.92 +2.6%	$12.50 +153.9%	+175.9%	$1.67B	$62.90M	N/A	60	News Coverage Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVTE) was last updated on 6/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aerovate Therapeutics (AVTE) Competitors

AVTE vs. QURE, GENB, BHVN, NUVB, and ABCL

How does Aerovate Therapeutics compare to uniQure?

Summary

How does Aerovate Therapeutics compare to Generate Biomedicines?

Summary

How does Aerovate Therapeutics compare to Biohaven?

Summary

How does Aerovate Therapeutics compare to Nuvation Bio?

Summary

How does Aerovate Therapeutics compare to AbCellera Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTE vs. The Competition

Aerovate Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aerovate Therapeutics (AVTE) Competitors

AVTE vs. QURE, GENB, BHVN, NUVB, and ABCL

How does Aerovate Therapeutics compare to uniQure?

Which has more risk & volatility, QURE or AVTE?

Do insiders & institutionals have more ownership in QURE or AVTE?

Which has better valuation & earnings, QURE or AVTE?

Is QURE or AVTE more profitable?

Do analysts rate QURE or AVTE?

Does the media prefer QURE or AVTE?

Summary

How does Aerovate Therapeutics compare to Generate Biomedicines?

Does the media favor AVTE or GENB?

Which has better earnings & valuation, AVTE or GENB?

Do analysts prefer AVTE or GENB?

Is AVTE or GENB more profitable?

Summary

How does Aerovate Therapeutics compare to Biohaven?

Do insiders & institutionals have more ownership in AVTE or BHVN?

Does the media refer more to AVTE or BHVN?

Which has more risk & volatility, AVTE or BHVN?

Do analysts prefer AVTE or BHVN?

Which has preferable valuation & earnings, AVTE or BHVN?

Is AVTE or BHVN more profitable?

Summary

How does Aerovate Therapeutics compare to Nuvation Bio?

Do institutionals & insiders believe in NUVB or AVTE?

Is NUVB or AVTE more profitable?

Does the media prefer NUVB or AVTE?

Which has more volatility and risk, NUVB or AVTE?

Which has stronger earnings & valuation, NUVB or AVTE?

Do analysts rate NUVB or AVTE?

Summary

How does Aerovate Therapeutics compare to AbCellera Biologics?

Do analysts rate AVTE or ABCL?

Do institutionals and insiders hold more shares of AVTE or ABCL?

Which has more risk & volatility, AVTE or ABCL?

Which has stronger valuation & earnings, AVTE or ABCL?

Is AVTE or ABCL more profitable?

Does the media favor AVTE or ABCL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTE vs. The Competition

Aerovate Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools